Edition:
United Kingdom

Cerecor Inc (CERC.OQ)

CERC.OQ on NASDAQ Stock Exchange Capital Market

1.91USD
14 Dec 2017
Change (% chg)

$-0.10 (-4.98%)
Prev Close
$2.01
Open
$1.99
Day's High
$2.03
Day's Low
$1.86
Volume
48,392
Avg. Vol
90,212
52-wk High
$2.63
52-wk Low
$0.34

Chart for

About

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $28.92
Shares Outstanding(Mil.): 26.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Cerecor announces leadership changes

* Cerecor Inc - ‍Interim Chief Executive Officer John Kaiser and Chief Medical Officer Dr. Ronald Marcus stepping down​

17 Nov 2017

BRIEF-Cerecor acquires TRX Pharmaceuticals

* Cerecor Inc - ‍Under terms of transactions, Cerecor will make an initial payment of $23 million for purchase of TRX​

17 Nov 2017

BRIEF-Cerecor reports Q3 earnings per share of $0.52

* As of Sept 30, cash and cash equivalents were $24.0 million, escrowed cash receivable was $3.75 million and current liabilities were $4.8 million​

06 Nov 2017

BRIEF-Cerecor Inc says Uli Hacksell retires as CEO, president

* Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer

14 Aug 2017

BRIEF-Cerecor Inc Q2 loss per share $0.14

* In August 2017, co sold its world-wide rights of CERC-501 to Janssen in exchange for an initial payment of $25 million​

14 Aug 2017

Earnings vs. Estimates